Receptors on NK cells

Natural Killer Cells: Basic Science and Clinical Application

Volumn , Issue , 2009, Pages 155-168

  Stern Ginossar, Noam ^a   Mandelboim, Ofer ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85137195083     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-370454-2.00011-9     Document Type: Chapter

References (137)

1. Achdout H., et al. Influenza virus infection augments NK cell inhibition through reorganization of major histocompatibility complex class I proteins. J Virol 2008, 82:8030-8037.
2. Aldemir H., et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol 2005, 175:7791-7795.
3. Arnon T.I., et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005, 6:515-523.
4. Arnon T.I., et al. The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood 2004, 103:664-672.
5. Arnon T.I., et al. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 2001, 31:2680-2689.
6. Augugliaro R., et al. Selective cross-talk among natural cytotoxicity receptors in human natural killer cells. Eur J Immunol 2003, 33:1235-1241.
7. Avril T., et al. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by siglecs-7 and -9, CD33-related siglecs expressed on human monocytes and NK cells. J Immunol 2004, 173:6841-6849.
8. Bauer S., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729.
9. Beauchemin N., et al. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res 1999, 252:243-249.
10. Biassoni R., et al. The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med 1996, 183:645-650.
11. Biassoni R., et al. Human natural killer cell receptors and co-receptors. Immunol Rev 2001, 181:203-214.
12. Biassoni R., et al. The murine homologue of the human NKp46, a triggering receptor involved in the induction of natural cytotoxicity. Eur J Immunol 1999, 29:1014-1020.
13. Bloushtain N., et al. Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 2004, 173:2392-2401.
14. Boissel N., et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 2006, 176:5108-5116.
15. Bottino C., et al. The human natural cytotoxicity receptors (NCR) that induce HLA class I-independent NK cell triggering. Hum Immunol 2000, 61:1-6.
16. Bottino C., et al. Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003, 198:557-567.
17. Boulton I.C., Gray-Owen S.D. Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nat Immunol 2002, 3:229-236.
18. Braud V., et al. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol 1997, 27:1164-1169.
19. Braud V.M., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799.
20. Brown M.H., et al. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med 1998, 188:2083-2090.
21. Bryceson Y.T., et al. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006, 107:159-166.
22. Butcher S., et al. MAFA-L, an ITIM-containing receptor encoded by the human NK cell gene complex and expressed by basophils and NK cells. Eur J Immunol 1998, 28:3755-3762.
23. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
24. Cantoni C., et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol 1999, 29:3148-3159.
25. Cantoni C., et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999, 189:787-796.
26. Cantoni C., et al. The three-dimensional structure of the human NK cell receptor NKp44, a triggering partner in natural cytotoxicity. Structure (Camb) 2003, 11:725-734.
27. Carretero M., et al. Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A: evidence for receptor function in heterologous transfectants. Eur J Immunol 1998, 28:1280-1291.
28. Castriconi R., et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A 2003, 100:4120-4125.
29. Cerwenka A., et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000, 12:721-727.
30. Chalupny N.J., et al. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun 2006, 346:175-181.
31. Chapman T.L., et al. Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2). Immunity 2000, 13:727-736.
32. Cohen G.B., et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999, 10:661-671.
33. Colonna M., et al. Inhibitory and activating receptors involved in immune surveillance by human NK and myeloid cells. J Leukoc Biol 1999, 66:718-722.
34. Colonna M., et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997, 186:1809-1818.
35. Colonna M., Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995, 268:405-408.
36. Cooper M.A., et al. NK cell and DC interactions. Trends Immunol 2004, 25:47-52.
37. Cordon-Cardo C., et al. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991, 51:6372-6380.
38. Cosman D., et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997, 7:273-282.
39. Crocker P.R., Varki A. Siglecs, sialic acids and innate immunity. Trends Immunol 2001, 22:337-342.
40. De Maria A., et al. Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors in Macaca fascicularis NK cells. Eur J Immunol 2001, 31:3546-3556.
41. Degli-Esposti M.A., Smyth M.J. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005, 5:112-124.
42. Diefenbach A., et al. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000, 1:119-126.
43. Doubrovina E.S., et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003, 171:6891-6899.
44. Dunn C., et al. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med 2003, 197:1427-1439.
45. Eagle R.A., Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007, 7:737-744.
46. Ebihara T., et al. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection. Int Immunol 2007, 19:1145-1155.
47. Falco M., et al. Identification of the rat homologue of the human NKp46 triggering receptor. Immunol Lett 1999, 68:411-414.
48. Ferlazzo G. Natural killer and dendritic cell liaison: recent insights and open questions. Immunol Lett 2005, 101:12-17.
49. Ferlazzo G., et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004, 172:1455-1462.
50. Ferlazzo G., et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002, 195:343-351.
51. Fernandez N.C., et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005, 105:4416-4423.
52. Foster C.E., et al. Crystal structure of the human natural killer (NK) cell activating receptor NKp46 reveals structural relationship to other leukocyte receptor complex immunoreceptors. J Biol Chem 2003, 278:46081-46086.
53. Fuchs A., et al. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol 2004, 172:3994-3998.
54. Fuchs A., et al. Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood 2005, 106:2076-2082.
55. Gasser S., et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
56. Gazit R., et al. Expression of KIR2DL1 on the entire NK cell population: a possible novel immunodeficiency syndrome. Blood 2004, 103:1965-1966.
57. Gonen-Gross T., et al. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol 2003, 171:1343-1351.
58. Groh V., et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A 1996, 93:12445-12450.
59. Groh V., et al. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001, 2:255-260.
60. Groh V., et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 1999, 96:6879-6884.
61. Groh V., et al. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998, 279:1737-1740.
62. Groh V., et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
63. Grundemann C., et al. Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol 2006, 176:1311-1315.
64. Guerra N., et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008, 28:571-580.
65. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999, 9:67-81.
66. Hanke T., et al. 2F1 antigen, the mouse homolog of the rat "mast cell function-associated antigen", is a lectin-like type II transmembrane receptor expressed by natural killer cells. Eur J Immunol 1998, 28:4409-4417.
67. Hanna J., et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006, 12:1065-1074.
68. Hewitt E.W. The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology 2003, 110:163-169.
69. Horng T., et al. NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat Immunol 2007, 8:1345-1352.
70. Ito M., et al. Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J Exp Med 2006, 203:289-295.
71. Jamieson A.M., et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002, 17:19-29.
72. Karre K., et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319:675-678.
73. Katz G., et al. MHC class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol 2004, 173:1819-1825.
74. Kim S., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
75. Lanier L.L. Natural killer cell receptor signaling. Curr Opin Immunol 2003, 15:308-314.
76. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
77. Lanier L.L., et al. Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 1994, 153:2417-2428.
78. Le Drean E., et al. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur J Immunol 1998, 28:264-276.
79. Lee N., et al. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 1998, 160:4951-4960.
80. Lee N., et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A 1998, 95:5199-5204.
81. Li P., et al. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol 2001, 2:443-451.
82. Liao N.S., et al. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 1991, 253:199-202.
83. Manaster I., et al. Endometrial NK cells are special immature cells that await pregnancy. J Immunol 2008, 181:1869-1876.
84. Mandelboim O., et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001, 409:1055-1060.
85. Mandelboim O., et al. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A 1999, 96:5640-5644.
86. Mandelboim O., et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med 1996, 184:913-922.
87. Markel G., et al. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 2002, 168:2803-2810.
88. Markel G., et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest 2002, 110:943-953.
89. Martin M.P., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002, 31:429-434.
90. Meyaard L. The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol 2008, 83:799-803.
91. Mizrahi S., et al. A phenotypic and functional characterization of NK cells in adenoids. J Leukoc Biol 2007, 82:1095-1105.
92. Moretta A., et al. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 2000, 21:228-234.
93. Moretta A., et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996, 14:619-648.
94. Moretta A., et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995, 182:875-884.
95. Moretta L., et al. Human natural killer cells: their origin, receptors and function. Eur J Immunol 2002, 32:1205-1211.
96. Moretta L., Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004, 23:255-259.
97. Nakajima H., et al. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol 2000, 30:3309-3318.
98. Nakajima H., et al. Activating interactions in human NK cell recognition: the role of 2B4-CD48. Eur J Immunol 1999, 29:1676-1683.
99. Nedvetzki S., et al. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 2007, 109:3776-3785.
100. Nicoll G., et al. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur J Immunol 2003, 33:1642-1648.
101. Nicoll G., et al. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem 1999, 274:34089-34095.
102. Parolini S., et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 2000, 192:337-346.
103. Pende D., et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001, 31:1076-1086.
104. Pende D., et al. Expression of the DNAM-1 ligands, nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 2006, 107:2030-2036.
105. Pende D., et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999, 190:1505-1516.
106. Pessino A., et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998, 188:953-960.
107. Pogge von Strandmann E., et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007, 27:965-974.
108. Poggi A., et al. IL-12-induced up-regulation of NKRP1A expression in human NK cells and consequent NKRP1A-mediated down-regulation of NK cell activation. Eur J Immunol 1998, 28:1611-1616.
109. Radaev S., et al. Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. Immunity 2001, 15:1039-1049.
110. Raulet D.H., et al. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001, 19:291-330.
111. Rosen D.B., et al. Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 2005, 175:7796-7799.
112. Rosen D.B., et al. Functional consequences of interactions between human NKR-P1A and its ligand LLT1 expressed on activated dendritic cells and B cells. J Immunol 2008, 180:6508-6517.
113. Sivori S., et al. 2B4 functions as a co-receptor in human NK cell activation. Eur J Immunol 2000, 30:787-793.
114. Sivori S., et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999, 29:1656-1666.
115. Sivori S., et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997, 186:1129-1136.
116. Stern-Ginossar N., et al. Host immune system gene targeting by a viral miRNA. Science 2007, 317:376-381.
117. Stern-Ginossar, N., et al. (2008). Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol.
118. Stern N., et al. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol 2005, 174:6692-6701.
119. Stewart C.A., et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A 2005, 102:13224-13229.
120. Sun J.C., Lanier L.L. Tolerance of NK cells encountering their viral ligand during development. J Exp Med 2008, 205:1819-1828.
121. Tahara-Hanaoka S., et al. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol 2004, 16:533-538.
122. Tangye S.G., et al. The CD2-subset of the Ig superfamily of cell surface molecules: receptor-ligand pairs expressed by NK cells and other immune cells. Semin Immunol 2000, 12:149-157.
123. Tomasec P., et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000, 287:1031.
124. Tomasec P., et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol 2005, 6:181-188.
125. Tripathy S.K., et al. Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J Exp Med 2008, 205:1829-1841.
126. Vales-Gomez M., et al. Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci U S A 1998, 95:14326-14331.
127. Veillette A. NK cell regulation by SLAM family receptors and SAP-related adapters. Immunol Rev 2006, 214:22-34.
128. Venkataraman G.M., et al. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol 2007, 178:961-969.
129. Vitale M., et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998, 187:2065-2072.
130. Vitale M., et al. Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol 2001, 31:233-242.
131. Vivier E., et al. Tyrosine phosphorylation of the Fc gamma RIII(CD16): zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing. J Immunol 1991, 146:206-210.
132. Welte S., et al. Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol 2006, 7:1334-1342.
133. Wills M.R., et al. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J Immunol 2005, 175:7457-7465.
134. Wu J., et al. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol 2003, 170:4196-4200.
135. Yokoyama W.M., et al. A family of murine NK cell receptors specific for target cell MHC class I molecules. Semin Immunol 1995, 7:89-101.
136. Yu M.C., et al. An essential function for beta-arrestin 2 in the inhibitory signaling of natural killer cells. Nat Immunol 2008, 9:898-907.
137. Zou Y., et al. Effect of human cytomegalovirus on expression of MHC class I-related chains A. J Immunol 2005, 174:3098-3104.